TScan Q4 net loss $35.8M; revenue down 90% YoY; heme relapse data positive

TScan Therapeutics, Inc.

Net loss $35.8M in Q4 vs $19.6M YoY; full-year net loss $127.5M vs $89.2M.
Revenue $0.7M Q4 vs $7.2M YoY; full-year $2.8M vs $21.0M, due to Amgen collaboration timing.
Cash, equivalents and marketable securities $290.1M; funding into Q1 2027.
ASH heme trial: 2/26 (8%) relapsed vs 4/12 (33%) control; HR 0.30.
IND cleared for MAGE-A4 TCR-T; closed $30M registered direct offering at 37% premium.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.